Search results for "Azepine"

showing 10 items of 266 documents

CCDC 1973338: Experimental Crystal Structure Determination

2020

Related Article: Imre Pápai, Petri M. Pihko, Juha H. Siitonen, Dániel Csókás|2020|Synlett|31|1581|doi:10.1055/s-0040-1707201

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(1R3aS10aR10bS)-1-methyloctahydro-2H-furo[32-c]pyrrolo[12-a]azepine-28(1H)-dioneExperimental 3D Coordinates
researchProduct

CCDC 2131015: Experimental Crystal Structure Determination

2022

Related Article: Braulio M. Puerta Lombardi, Ethan R. Pezoulas, Roope A. Suvinen, Alexander Harrison, Zachary S. Dubrawski, Benjamin S. Gelfand, Heikki M. Tuononen, Roland Roesler|2022|Chem.Commun.|58|6482|doi:10.1039/D2CC01476A

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters18-bis[26-bis(propan-2-yl)phenyl]-2277-tetramethyldecahydro-1H-3a5a-ethanodipyrrolo[23-b:3'2'-f]azepineExperimental 3D Coordinates
researchProduct

CCDC 1915324: Experimental Crystal Structure Determination

2019

Related Article: U. Kolb, Y. Krysiak, S. Plana-Ruiz|2019|Acta Crystallogr.,Sect.B:Struct.Sci.,Cryst.Eng. and Mat.|75|463|doi:10.1107/S2052520619006711

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters5H-dibenzo[bf]azepine-5-carboxamideExperimental 3D Coordinates
researchProduct

CCDC 1453056: Experimental Crystal Structure Determination

2016

Related Article: Lei Wang, Sun Li, Marcus Blümel, Arne R. Philipps, Ai Wang, Rakesh Puttreddy, Kari Rissanen, Dieter Enders|2016|Angew.Chem.,Int.Ed.|55|11110|doi:10.1002/anie.201604819

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters9-methyl-1-((4-methylphenyl)sulfonyl)-1'-phenyl-15-dihydrospiro[1-benzazepine-43'-indole]-22'(1'H3H)-dione ethanol solvateExperimental 3D Coordinates
researchProduct

CCDC 840881: Experimental Crystal Structure Determination

2012

Related Article: M.Cieslikiewicz, A.Bouet, S.Juge, M.Toffano, J.Bayardon, C.West, K.Lewinski, I.Gillaizeau|2012|Eur.J.Org.Chem.|2012|1101|doi:10.1002/ejoc.201101293

Space GroupCrystallographyCrystal SystemMethyl 7-(1-oxo-25-diphenylphospholan-1-yl)-2345-tetrahydro-1H-azepine-1-carboxylateCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 840882: Experimental Crystal Structure Determination

2012

Related Article: M.Cieslikiewicz, A.Bouet, S.Juge, M.Toffano, J.Bayardon, C.West, K.Lewinski, I.Gillaizeau|2012|Eur.J.Org.Chem.|2012|1101|doi:10.1002/ejoc.201101293

Space GroupCrystallographyCrystal Systemt-Butyl 7-(lambda^5^-boranyl(2-methoxyphenyl)phenylphosphoranyl)-2345-tetrahydro-1H-azepine-1-carboxylateCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Evaluation of carbamazepine uptake and metabolization by Typha spp., a plant with potential use in phytotreatment

2011

Abstract Phytoremediation technologies such as constructed wetlands have shown higher efficiencies in removal of pharmaceuticals from wastewaters than conventional wastewater treatment processes, and plants seem to have an important role in the removal of some of those compounds. In this context, a study was conducted to assess tolerance, uptake, and metabolism of the epilepsy drug, carbamazepine, by the macrophyte Typha spp. This evaluation was conducted in hydroponic solutions with 0.5–2.0 mg/L of this pharmaceutical for a maximum period of 21 days. The removal of carbamazepine from nutrient solutions by the plants reached values of 82% of the initial contents. Furthermore, a metabolite (…

Spectrometry Mass Electrospray IonizationEnvironmental EngineeringMetaboliteBioengineeringContext (language use)Typhaceaechemistry.chemical_compoundNutrientTandem Mass SpectrometryBotanymedicineTypha spp.Waste Management and DisposalTyphaPhytotreatmentbiologyConstructed wetlandsRenewable Energy Sustainability and the EnvironmentGeneral MedicineCarbamazepinebiology.organism_classificationPhytoremediationPhytoremediationBiodegradation EnvironmentalCarbamazepinechemistryCatalaseOxidative stressEnvironmental chemistrybiology.proteinPharmaceuticalsAnticonvulsantsWater Pollutants ChemicalChromatography Liquidmedicine.drug
researchProduct

Characterization of the binding of benzodiazepines to human serum albumin

1973

The binding of eleven benzodiazepine derivatives to human serum albumin (HSA) was determined by means of sephadex gel filtration. The albumin binding of the substances was characterized by the percentage of bound drug, the binding constants k +, K 1 and m, the number of binding sites per albumin molecule, and the free binding energy. Under the conditions chosen in these experiments there seems to exist only one binding site of the same type for all investigated benzodiazepines at the HSA molecule. The affinities of the benzodiazepines to this binding site are very different. It is discussed which part of the benzodiazepine molecule represents the main binding group.

StereochemistryBinding energySerum albuminPlasma protein bindingFlurazepammedicineHumansNitrazepamBovine serum albuminBinding siteSerum AlbuminPharmacologyBinding SitesbiologyOxazepamChemistryAlbuminChlordiazepoxideGeneral MedicineBenzazepinesHuman serum albuminSephadexChromatography Gelbiology.proteinProtein Bindingmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Synthesis and Dopamine Receptor Selectivity of the Benzyltetrahydroisoquinoline, (R)-(+)-nor-Roefractine

1998

(R)-(+)-nor-Roefractine (1) was synthesized by the Bischler-Napieralski route, using asymmetric reduction of the 1, 2-didehydro precursor imine with sodium (S)-N-CBZ-prolinyloxyborohydride. Compound 1 was able to displace [3H]-raclopride (a D2 dopamine receptor-selective ligand) from its specific binding sites in rat striatum with selectivity vs [3H]-SCH23390 (D1 dopamine receptor-selective ligand).

StereochemistryImineMolecular ConformationPharmaceutical ScienceLigandsBinding CompetitiveChemical synthesisAnalytical Chemistrychemistry.chemical_compoundDopamineDrug DiscoverymedicinePharmacologyBicyclic moleculeReceptors Dopamine D2LigandOrganic ChemistryBenzazepinesIsoquinolinesComplementary and alternative medicinechemistryDopamine receptorDopamine AntagonistsMolecular MedicineIndicators and ReagentsEnantiomerSelectivitymedicine.drugJournal of Natural Products
researchProduct

Synthesis, benzodiazepine receptor binding and molecular modelling of isochromeno[4,3-c]pyrazol-5(1H)-one derivatives

2012

Abstract A series of isochromeno[4,3-c]pyrazole-5(1H)-one derivatives 7b–h were prepared and tested at 10 μM for their ability to displace specific [3H]flunitrazepam from bovine brain membranes. The substitution pattern of the above derivatives was shown to influence the receptor affinity. The most active compound of the series was 7e, showing a 54% inhibition of [3H]flunitrazepam binding. Compounds 7a–d,i were compared with the known isomers chromeno[4,3-c]pyrazole-4(1H)-ones 14a–d,i, showing that the isochromene/chromene isomerism influences the activity.

StereochemistryProtein ConformationChemistry Techniques SyntheticIsochromeno[43-c]pirazoles Dihydrospiro[isoindole-13’-pyrazol]-3(2H)- ones Benzodiazepine receptorDrug DiscoverymedicineAnimalsHumansBenzopyransReceptorBenzodiazepine receptor bindingPharmacologyChemistryOrganic ChemistryGeneral MedicineReceptors GABA-ASettore CHIM/08 - Chimica FarmaceuticaMolecular Docking SimulationMembraneBovine brainActive compoundPyrazolesCattleFlunitrazepam bindingFlunitrazepammedicine.drugProtein Binding
researchProduct